Biomedicines (Nov 2021)

Cell and Cell Free Therapies in Osteoarthritis

  • Pau Peláez,
  • Elena Damiá,
  • Marta Torres-Torrillas,
  • Deborah Chicharro,
  • Belén Cuervo,
  • Laura Miguel,
  • Ayla del Romero,
  • Jose Maria Carrillo,
  • Joaquín J. Sopena,
  • Mónica Rubio

DOI
https://doi.org/10.3390/biomedicines9111726
Journal volume & issue
Vol. 9, no. 11
p. 1726

Abstract

Read online

Osteoarthritis (OA) is the most common articular disease in adults and has a current prevalence of 12% in the population over 65 years old. This chronic disease causes damage to articular cartilage and synovial joints, causing pain and leading to a negative impact on patients’ function, decreasing quality of life. There are many limitations regarding OA conventional therapies—pharmacological therapy can cause gastrointestinal, renal, and cardiac adverse effects, and some of them could even be a threat to life. On the other hand, surgical options, such as microfracture, have been used for the last 20 years, but hyaline cartilage has a limited regeneration capacity. In recent years, the interest in new therapies, such as cell-based and cell-free therapies, has been considerably increasing. The purpose of this review is to describe and compare bioregenerative therapies’ efficacy for OA, with particular emphasis on the use of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP). In OA, these therapies might be an alternative and less invasive treatment than surgery, and a more effective option than conventional therapies.

Keywords